Tag:
Novartis
Latest Headlines
Latest Headlines
Even some domestic firms rail at India's price control plan
India's plan to again put price controls on the majority of the drugs in the country has become a flash point for companies there as well as Western drugmakers.
Indian gov't probes drug regulator after scathing review
Days after a parliamentary report noted shoddy oversight of approvals, the Indian government has mounted an investigation into the alleged misdeeds. Meanwhile, big names in biopharma have surfaced in the sea of allegations.
India's drug regulator says it will clean up its act
India's health agency has vowed that its top drug regulator will clean up its act, saying it will cinch up oversight rules for letting drugs on the market.
Indian panel accuses Big Pharma of colluding with regulators
An Indian government report has hit the domestic pharma business like a whirlwind--and sucked Big Pharma into the fury.
Subpar clinical trials probed in India's review of regulation
Indian lawmakers and patient advocates charge that their regulator rubber-stamped drugs to be sold in the county without required clinical trials.
Drug manufacturing problems bad for business but good for jobs
Problems plaguing drug manufacturers are bad for business but apparently good for the job market.
Novartis may weigh Lucentis price cut in U.K.
Last week, data comparing that product to its close cousin, Avastin, in macular degeneration patients found the two meds roughly equivalent, efficacy-wise. This week, a U.K study concluded that the two offered similar results with a similar safety profile.
Pharma continues parachute-building for patent cliff
Last month was a big one for pharma dealmaking, as anyone following the industry well knows. The list of deals, bids and potential deals is long--$33 billion long.
Novartis passes Phase III test for rare-disorder drug
The Swiss drug giant says its experimental drug pasireotide LAR beat the standard of care in the largest Phase III study involving patients with acromegaly.
Novartis now top dog in skin drugs with $1.5B Fougera buy
Novartis has snapped up Fougera Pharmaceuticals, a U.S.-based maker of generic skin treatments, for $1.5 billion.
